307 related articles for article (PubMed ID: 34901191)
1. The Updates of Podocyte Lipid Metabolism in Proteinuric Kidney Disease.
Sun Y; Cui S; Hou Y; Yi F
Kidney Dis (Basel); 2021 Nov; 7(6):438-451. PubMed ID: 34901191
[TBL] [Abstract][Full Text] [Related]
2. Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy.
Jiang H; Shen Z; Zhuang J; Lu C; Qu Y; Xu C; Yang S; Tian X
Front Immunol; 2023; 14():1335936. PubMed ID: 38288116
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylases Take Center Stage on Regulation of Podocyte Function.
Liu M; Qiao Z; Zhang Y; Zhan P; Yi F
Kidney Dis (Basel); 2020 Jul; 6(4):236-246. PubMed ID: 32903938
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of podocyte injury and implications for diabetic nephropathy.
Barutta F; Bellini S; Gruden G
Clin Sci (Lond); 2022 Apr; 136(7):493-520. PubMed ID: 35415751
[TBL] [Abstract][Full Text] [Related]
5. Dock5 Deficiency Promotes Proteinuric Kidney Diseases via Modulating Podocyte Lipid Metabolism.
Qu H; Liu X; Zhu J; Xiong X; Li L; He Q; Wang Y; Yang G; Zhang L; Yang Q; Luo G; Zheng Y; Zheng H
Adv Sci (Weinh); 2024 Mar; 11(11):e2306365. PubMed ID: 38161229
[TBL] [Abstract][Full Text] [Related]
6. Interplay of lipid metabolism and inflammation in podocyte injury.
Luo Z; Chen Z; Hu J; Ding G
Metabolism; 2024 Jan; 150():155718. PubMed ID: 37925142
[TBL] [Abstract][Full Text] [Related]
7. Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases.
Sever S; Schiffer M
Kidney Int; 2018 Jun; 93(6):1298-1307. PubMed ID: 29678354
[TBL] [Abstract][Full Text] [Related]
8. Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease.
Tian X; Ishibe S
Nephrol Dial Transplant; 2016 Oct; 31(10):1577-83. PubMed ID: 26968197
[TBL] [Abstract][Full Text] [Related]
9. Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress.
Raij L; Tian R; Wong JS; He JC; Campbell KN
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1308-F1317. PubMed ID: 27335373
[TBL] [Abstract][Full Text] [Related]
10. Fn14 in podocytes and proteinuric kidney disease.
Sanchez-Niño MD; Poveda J; Sanz AB; Mezzano S; Carrasco S; Fernandez-Fernandez B; Burkly LC; Nair V; Kretzler M; Hodgin JB; Ruiz-Ortega M; Selgas R; Egido J; Ortiz A
Biochim Biophys Acta; 2013 Dec; 1832(12):2232-43. PubMed ID: 23999007
[TBL] [Abstract][Full Text] [Related]
11. Wnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease.
Zhou L; Liu Y
Nat Rev Nephrol; 2015 Sep; 11(9):535-45. PubMed ID: 26055352
[TBL] [Abstract][Full Text] [Related]
12. Podocytopathy: The role of actin cytoskeleton.
Ahmadian E; Eftekhari A; Atakishizada S; Valiyeva M; Ardalan M; Khalilov R; Kavetskyy T
Biomed Pharmacother; 2022 Dec; 156():113920. PubMed ID: 36411613
[TBL] [Abstract][Full Text] [Related]
13. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.
Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN
J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981
[TBL] [Abstract][Full Text] [Related]
14. [The role of podocyte injury in chronic kidney disease].
Asanuma K
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(1):26-36. PubMed ID: 25765686
[TBL] [Abstract][Full Text] [Related]
15. Renal Lipotoxicity-Associated Inflammation and Insulin Resistance Affects Actin Cytoskeleton Organization in Podocytes.
Martínez-García C; Izquierdo-Lahuerta A; Vivas Y; Velasco I; Yeo TK; Chen S; Medina-Gomez G
PLoS One; 2015; 10(11):e0142291. PubMed ID: 26545114
[TBL] [Abstract][Full Text] [Related]
16. Sirtuins as novel pharmacological targets in podocyte injury and related glomerular diseases.
Liu T; Yang L; Mao H; Ma F; Wang Y; Li S; Li P; Zhan Y
Biomed Pharmacother; 2022 Nov; 155():113620. PubMed ID: 36122519
[TBL] [Abstract][Full Text] [Related]
17. Deficiency of Mitochondrial Glycerol 3-Phosphate Dehydrogenase Exacerbates Podocyte Injury and the Progression of Diabetic Kidney Disease.
Qu H; Gong X; Liu X; Zhang R; Wang Y; Huang B; Zhang L; Zheng H; Zheng Y
Diabetes; 2021 Jun; 70(6):1372-1387. PubMed ID: 33741719
[TBL] [Abstract][Full Text] [Related]
18. Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling.
Liu M; Liang K; Zhen J; Zhou M; Wang X; Wang Z; Wei X; Zhang Y; Sun Y; Zhou Z; Su H; Zhang C; Li N; Gao C; Peng J; Yi F
Nat Commun; 2017 Sep; 8(1):413. PubMed ID: 28871079
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
[TBL] [Abstract][Full Text] [Related]
20. The podocyte's response to injury: role in proteinuria and glomerulosclerosis.
Shankland SJ
Kidney Int; 2006 Jun; 69(12):2131-47. PubMed ID: 16688120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
